deerfield.com (singulargenomics.com)
Domain: singulargenomics.com
Sektör: Teknoloji
Saldırı Tarihi: 18.12.2025
Açıklama Tarihi: 18.12.2025
Açıklama: Singular Genomics
https://www.singulargenomics.com/
The company, known for its next-generation sequencing technologies such as the G4® Sequencing Platform and the upcoming G4X™ Spatial Sequencer, is now focused on further innovation in genomic and spatial multiomics research.
Singular Genomics Systems, Inc. is a life science technology company founded in 2016 that develops next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians in advancing science and medicine.
The company's mission centers on leveraging its proprietary Sequencing Engine platform, which underpins its core product tenets of accuracy, speed, flexibility, and scale.
Its commercially available G4 Sequencing Platform is a benchtop genomic sequencer designed for fast and accurate results, while the G4X Spatial Sequencer, an upgrade to the G4 platform, enables high-throughput in situ direct sequencing of RNA, targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.
The company is also developing the PX Integrated Solution, a multiomics platform that combines single-cell analysis, spatial analysis, genomics, and proteomics in one instrument.
As of February 21, 2025, Singular Genomics was taken private following the closing of an acquisition by Deerfield Management.
The company is headquartered in San Diego, California, with additional operations in La Jolla.
Target CEO:
Drew Spaventa
https://www.linkedin.com/in/drew-spaventa-98087213/
Josh Stahl
https://www.linkedin.com/in/joshua-stahl-77238627/
Target Owner:
James E. Flynn
https://www.linkedin.com/in/james-flynn-99304a72/
Deerfield Management Company, L.P.
Singular Genomics is currently owned by Deerfield Management Company, L.P., following the completion of its acquisition on February 21, 2025.
The transaction involved an affiliate of Deerfield acquiring all outstanding shares of Singular Genomics common stock not already owned by Deerfield for $20.00 per share in cash.
As a result, Singular Genomics transitioned from a publicly traded company to a private entity, with the goal of providing greater strategic flexibility.
The company's new leadership includes Josh Stahl as Chief Executive Officer and Drew Spaventa, the co-founder, continuing on the board as a special advisor to the CEO.
The data affected by this breach includes:
Source Codes
Biological Data
Experemental Data
Client Data
Personal Data (PII)
Staff Data
Financial Data
Proposal Contracts
NDA's
Internal Documents
Service Agreements
Breach size:
20TB
Breach review:
Singular Genomics Systems, Inc., a U.S.-based life-science technology company developing high-throughput spatial multiomics and next-generation sequencing platforms, experienced a data breach discovered on September 11, 2025.
The threat actor involved was identified as INC_RANSOM.
The breach is currently under investigation, and the leak size remains unknown.
The incident highlights growing concerns about cybersecurity in the genomics sector, where biological data is increasingly processed through digital pipelines vulnerable to cyber threats.
https://www.breachsense.com/breaches/singular-genomics-systems-data-breach/
Research Genomes:
Bacillus_cereus
bcereus
clost
danio_rerio
ecoli
epr
grch38
metaphlan4_databases
mm10
Mycobacterium_tuberculosis
phep
phix
phixil
plasmodium_falciparum
pse
rhodo
Rhodobacter_sphaeroides
roche
ruber
sal
spc
staph
synthetic_allen
synthetic_allen_hp1
synthetic_allen_hp2
tb
This company does not show any interest in solving its problem. She doesn't care about the security of her data and the research of her customers.
